Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001711279-24-000056
Filing Date
2024-11-04
Accepted
2024-11-04 08:05:26
Documents
67
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q krys-20240930.htm   iXBRL 10-Q 1484912
2 EX-31.1 a3q24krysex311.htm EX-31.1 10682
3 EX-31.2 a3q24krysex312.htm EX-31.2 10645
4 EX-32.1 a3q24krysex321.htm EX-32.1 11166
  Complete submission text file 0001711279-24-000056.txt   6401968

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT krys-20240930.xsd EX-101.SCH 37454
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT krys-20240930_cal.xml EX-101.CAL 68082
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT krys-20240930_def.xml EX-101.DEF 165744
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT krys-20240930_lab.xml EX-101.LAB 554289
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT krys-20240930_pre.xml EX-101.PRE 359843
70 EXTRACTED XBRL INSTANCE DOCUMENT krys-20240930_htm.xml XML 871014
Mailing Address 2100 WHARTON STREET SUITE 701 PITTSBURGH PA 15203
Business Address 2100 WHARTON STREET SUITE 701 PITTSBURGH PA 15203 (412) 586-5830
Krystal Biotech, Inc. (Filer) CIK: 0001711279 (see all company filings)

EIN.: 821080209 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38210 | Film No.: 241420804
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)